Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial

Ashley M. Hopkins, Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)
5 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences